These 2 biotech stocks benefit from Moderna's breakthrough in cancer treatment!
Reading Time: 3 minutes
The Nasdaq Biotech Index rose by +4% yesterday. Moderna announced a breakthrough in individualized cancer therapy. It is the first positive Phase III evidence for a personalized mRNA therapy. Which stocks will benefit? This is how individualized mRNA cancer therapy works: The patient’s tumor tissue and blood are collected. The genetic material of the tumor is compared with the normal genetic material from the blood. Moderna explicitly describes tumor DNA sequencing, normal DNA sequencing, and tumor RNA sequencing using Next Generation Sequencing...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
